ARTICLE | Targets & Mechanisms
CXCR2 antibodies for antitumor immunity
June 19, 2014 7:00 AM UTC
A National Cancer Institute team has found a new chemokine-regulated pathway of tumor immune evasion that could account for some patients' resistance to checkpoint inhibitor-based therapies.1 By blocking CXC chemokine receptor 2, the team prevented migration of myeloid-derived suppressor cells and increased the efficacy of programmed cell death 1-targeting mAbs in a mouse model of rhabdomyosarcoma.
The researchers are now planning to test anti-CXC chemokine receptor 2 (CXCR2; IL8RB) antibodies in combination with other cancer immunotherapies...